$DGX insider trading
Over the last 12 months, Quest Diagnostics insiders reported no purchases and 24 sales totaling $42.6M across SEC Form 4 filings. 88% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $42.6M 24 events
- Events · 12m
- 24 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 88% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Davis J. E.CEO and President · O·D | ▼ Sale | 10,000 | $242.72 | $2.4M | -7.6% | plan |
| Aug 28, 2026 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 22,677 | $243.11 | $5.5M | -37.6% | plan · 3 tranches |
| Jul 28, 2026 | DELANEY MARK ESVP & Chief Commercial Officer · O | ▼ Sale | 1,600 | $235.18 | $376K | -13.4% | plan |
| Jun 4, 2026 | KUPPUSAMY KARTHIKSVP, Clinical Solutions · O | ▼ Sale | 8,147 | $200 | $1.6M | -37.6% | plan |
| Jun 1, 2026 | Davis J. E.CEO and President · O·D | ▼ Sale | 10,000 | $194.14 | $1.9M | -7% | plan |
| Mar 5, 2026 | Doherty Catherine T.EVP, Regional Businesses · O | ▼ Sale | 5,558 | $206.21 | $1.1M | -7.6% | plan |
| Mar 5, 2026 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 3,878 | $206.21 | $800K | -9.4% | plan |
| Mar 5, 2026 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 2,855 | $206.21 | $589K | -15.8% | plan |
| Mar 4, 2026 | KUPPUSAMY KARTHIKSVP, Clinical Solutions · O | ▼ Sale | 2,628 | $204.86 | $538K | -16.4% | — |
| Mar 3, 2026 | Doherty Catherine T.EVP, Regional Businesses · O | ▼ Sale | 632 | $207.73 | $131K | -0.9% | plan |
| Mar 3, 2026 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 526 | $207.73 | $109K | -1.4% | plan |
| Mar 3, 2026 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 410 | $207.73 | $85K | -2.6% | plan |
| Mar 2, 2026 | Davis J. E.CEO and President · O·D | ▼ Sale | 10,000 | $212.52 | $2.1M | -7.9% | plan |
| Feb 19, 2026 | Doherty Catherine T.EVP, Regional Businesses · O | ▼ Sale | 1,433 | $204.83 | $294K | -2.1% | plan |
| Feb 19, 2026 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 958 | $204.83 | $196K | -5.7% | plan |
| Feb 19, 2026 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 1,111 | $204.83 | $228K | -2.8% | plan |
| Feb 13, 2026 | Doherty Catherine T.EVP, Regional Businesses · O | ▼ Sale | 26,165 | $206.15 | $5.4M | -27.8% | plan · 5 tranches |
| Feb 10, 2026 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 5,662 | $204 | $1.2M | -26.9% | plan |
| Nov 25, 2025 | Davis J. E.CEO and President · O·D | ▼ Sale | 55,093 | $192.22 | $10.6M | -31.4% | plan · 3 tranches |
| Nov 25, 2025 | Gregg Vicky BD | ▼ Sale | 1,250 | $191.76 | $240K | -6.8% | — |
| Nov 18, 2025 | DELANEY MARK ESVP & Chief Commercial Officer · O | ▼ Sale | 7,946 | $187.35 | $1.5M | -51.3% | plan |
| Oct 22, 2025 | PFEIFFER GARY MD | ▼ Sale | 1,482 | $182.4 | $270K | -4.8% | — |
| Sep 26, 2025 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 227 | $188.13 | $43K | -0.6% | plan · 2 tranches |
| Sep 24, 2025 | PREVOZNIK MICHAEL ESVP & General Counsel · O | ▼ Sale | 28,463 | $187.12 | $5.3M | -42.8% | plan · 2 tranches |
| Aug 21, 2025 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 1,975 | $185 | $365K | -11.5% | plan |
| Aug 19, 2025 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 4,532 | $183 | $829K | -20.8% | plan |
| Aug 15, 2025 | Plewman PatrickSVP for Diagnostic Services · O | ▼ Sale | 1,975 | $180 | $356K | -10.3% | plan |
Every $DGX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Quest Diagnostics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DGX feed.